107367-98-6

Basic information

• Product Name: 2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ACETIC ACID
• Synonyms: 2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ACETIC ACID;(5-METHYL-2-PHENYLOXAZOL-4-YL)ACETIC ACID;BUTTPARK 37\06-80;(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ACETIC ACID;2-(5-Methyl-2-phenyl-oxazol-4-yl)-acetic acid
• CAS NO: 107367-98-6
• Molecular Formula: C₁₂H₁₁NO₃
• Molecular Weight: 217.22
• Product Categories: Carboxylic Acids;Oxazoles, Isoxazoles & Benzoxazoles;Carboxylic Acids;Oxazoles, Isoxazoles & Benzoxazoles
• Mol File: 107367-98-6.mol
• Article Data: 11

Chemical Properties

• Melting Point: 131 °C
• Boiling Point: 411.7 °C at 760 mmHg
• Flash Point: 202.8 °C
• Appearance: /
• Density: 1.245 g/cm³
• Vapor Pressure: 1.63E-07mmHg at 25°C
• Refractive Index: 1.569
• Storage Temp.: 2-8°C
• PKA: 3.80±0.10(Predicted)
• CAS DataBase Reference: 2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ACETIC ACID(107367-98-6)
• EPA Substance Registry System: 2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ACETIC ACID(107367-98-6)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 107367-98-6(Hazardous Substances Data)

Usage

General Description

2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetic acid is a chemical compound with an oxazole ring, which is a five-membered heterocyclic ring containing one oxygen atom, one nitrogen atom, and three carbon atoms. The particular compound includes a 5-methyl-2-phenyl modification on the oxazole ring, and an acetic acid ester connected on the 2nd carbon atom. This specific compound has not been widely studied, so its physical properties and potential uses are not well-known. However, oxazoles in general are key structures in various natural and synthetic bioactive compounds with diverse therapeutic benefits, indicating the potential importance of future research in this compound.

InChI:InChI=1/C12H11NO3/c1-8-10(7-11(14)15)13-12(16-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3,(H,14,15)

Upstream product

• 100-52-7 benzaldehyde 
• 186895-16-9 5-Methyl-4-hydroxyethyl-2-phenyl-oxazole 
• 258346-54-2 3-(5-methyl-2-phenyl-4-oxazolyl)propionitrile 
• 100373-13-5 methyl 3-benzamido-4-oxovalerate 
• 54819-26-0 methyl 3-(benzoylamino)-4-oxovalerate 
• 98-88-4 benzoyl chloride 
• 39741-26-9 N-benzoyl-L-aspartic acid β-methyl ester 
• 103788-61-0 (5-methyl-2-phenyl-4-oxazolyl)methyl chloride 
• 27492-46-2 4,5-dimethyl-2-phenyl-oxazole 3-oxide 
• 524959-64-6 2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetonitrile 
• 103788-64-3 methyl 2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetate 

Downstream Products

• 1394014-09-5 C₂₅H₂₈N₂O₅ 
• 1394014-10-8 C₂₅H₂₈N₂O₅ 
• 1394014-11-9 C₂₆H₂₈N₂O₅ 
• 1394014-12-0 C₂₆H₂₈N₂O₅ 
• 888707-94-6 C₂₄H₂₆N₂O₅ 
• 888707-96-8 C₂₄H₂₆N₂O₅ 
• 888708-07-4 C₂₅H₂₈N₂O₅ 
• 888708-09-6 C₂₅H₂₈N₂O₅ 
• 1584693-24-2 ethyl 4-(5-methyl-2-phenyl-1,3-oxazol-4-yl)-3-oxobutanoate 
• 1415228-22-6 C₂₄H₂₆N₂O₅ 
• 1415228-26-0 C₂₂H₂₂N₂O₅ 
• 1394014-05-1 C₂₅H₂₈N₂O₅ 
• 1394014-06-2 C₂₅H₂₈N₂O₅ 
• 888707-86-6 C₂₆H₃₀N₂O₅ 

Relevant articles and documents

Design and synthesis of Oxime ethers of β-oxo-γ-phenylbutanoic acids as PPAR a and -γ dual agonists

Oxime ethers of p-oxo-y-phenylbutanoic acids were prepared to develop more effective PPAR a and y dual agonists. Among them, compound 11k exhibited potent in vitro activities with EC50 of 2.5 nM and 3.3 nM in PPAR a and y, respectively. It showed better g

Design and synthesis of oxime ethers of α-acyl-β-phenylpropanoic acids as PPAR dual agonists

Oxime ethers of α-acyl-β-phenylpropanoic acids were prepared to apply as PPARα and γ dual agonists. Among them, compound 11l proved to exhibit potent in vitro activities with EC50 of 19 and 13 nM in PPARα and γ, respectively. It showed better g

Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis

The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazolidinedione analogs that have been designed to include esters within the structure of the compounds are provided. This invention is also drawn to methods of treating disorders, such as diabetes, comprising the administration of therapeutically effective compositions comprising compounds that have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester-containing thiazolidinedione analogs are also taught.